Harrow Health, Inc. (HROW)
Chart Events
Performance Outlook
| Previous Close | 7.28 |
| Open | 7.32 |
| Bid | 6.29 x 900 |
| Ask | 12.00 x 900 |
| Day's Range | 7.06 - 7.31 |
| 52 Week Range | 5.40 - 12.99 |
| Volume | |
| Avg. Volume | 128,208 |
| Market Cap | 193.002M |
| Beta (5Y Monthly) | 0.90 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.78 |
| Earnings Date | Aug 08, 2022 - Aug 12, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17.38 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for HROW
Related Research
- Harrow Health, Inc.Daily – Vickers Top Buyers & Sellers for 06/29/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat6 days agoArgus Research
- Business Wire
Harrow Health Announces Launch of IOPIDINE® 1% and MAXITROL® in the United States
NASHVILLE, Tenn., June 24, 2022--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced the completion of the transfer to Harrow of the New Drug Applications (NDAs) of recently acquired, FDA-approved ophthalmic medicines, IOPIDINE® 1%, MAXITROL® 3.5mg/10,000 units/0.1%, and MOXEZA® 0.5%. Harrow also announced that IOPIDINE 1% and MAXITROL are now commercially available; Harrow intends to commercialize MOXEZA 0.5% at a later date. Harrow purchased these medi
- InvestorPlace
7 Mighty Micro-Cap Stocks That Could Be Future Moonshots
Source: iQoncept / Shutterstock.com Given the way the market’s acting today, now may not seem like the best time to pursue “moonshot” plays. Rising interest rates keep putting pressure on formerly high-flying growth stocks. Meme stocks are struggling to hold onto what’s left of their “to the moon” gains. Yet for investors, there’s an area that may provide such high-risk, high-potential opportunities: micro-cap stocks. Micro-caps, or stocks with market capitalizations under $300 million, are an u
- Simply Wall St.
Is Harrow Health, Inc.'s (NASDAQ:HROW) Shareholder Ownership Skewed Towards Insiders?
Every investor in Harrow Health, Inc. ( NASDAQ:HROW ) should be aware of the most powerful shareholder groups...
